20cm速递｜科创创新药ETF国泰（589720）盘中涨近2%，连续10日净流入近4亿元，中国创新出海迎来开门红

Group 1 - The core viewpoint of the news highlights the significant growth and potential of China's innovative pharmaceuticals, particularly in the context of international expansion and investment confidence [1] - The year 2025 is marked as a pivotal year for China's innovative pharmaceuticals, with total outbound licensing transaction amounts reaching $135.655 billion and a record 157 transactions [1] - The continuous successful BD transactions validate the global competitiveness of Chinese innovative drugs, supporting long-term investment confidence [1] Group 2 - The small nucleic acid drug sector is making notable progress, with leading companies accelerating their development in new target discovery and treatment convenience, attracting increased attention [1] - The GLP-1 sector is expected to have long-term market potential following the establishment of a new pricing system [1] - Domestic companies are actively pursuing relevant targets in the oral autoimmune drug space, indicating significant value [1] Group 3 - The brain-computer interface technology is at a critical juncture for industrialization, with substantial advancements in policy support, device approval, insurance coverage, and clinical applications [1] - Developments in radiation therapy equipment technology are creating new market opportunities worth billions [1] Group 4 - The ETF Guotai (589720) tracks the innovative drug index (950161), which includes listed companies engaged in innovative drug research and development, covering various fields such as biopharmaceuticals, chemical drugs, and traditional Chinese medicine [2] - The index reflects the overall performance of listed companies in China's pharmaceutical innovation sector [2]